强生(JNJ.US)加入降价药企阵营：与特朗普政府达成协议，以换取关税豁免

Core Viewpoint - Johnson & Johnson (JNJ.US) has reached an agreement with the Trump administration to lower drug prices in exchange for tariff exemptions, following similar agreements by other pharmaceutical companies [1] Group 1: Company Agreements - Johnson & Johnson is the latest pharmaceutical company to agree to lower drug prices, joining GlaxoSmithKline (GSK.US), Merck (MRK.US), and Novartis (NVS.US) [1] - Pfizer (PFE.US) and AstraZeneca (AZN.US) were among the first to agree to reduce prescription drug prices for tariff relief [1] - Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) also reached agreements to significantly lower prices for commonly used GLP-1 weight loss drugs for Medicare, Medicaid, and out-of-pocket patients [1]